Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AusperBio Reports on Antisense Oligonucleotide that Targets HBV mRNA

publication date: Jul 8, 2024

AusperBio, a Hangzhou-Boston biotech, reported its lead drug, an unconjugated antisense oligonucleotide (ASO) that targets all HBV mRNA, has now treated 193 participants in global and China clinical trials. The patient base includes 101 participants with chronic HBV. AHB-137 is designed to trigger the degradation of all HBV RN. The candidate is a novel unconjugated antisense oligonucleotide (ASO) with a dual mechanism the could become a backbone for novel therapies that aim to find a functional cure for CHB. The novel ASO is currently in a global Phase Ib trial and a Phase II trial in China. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here